Status:
COMPLETED
Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method
Lead Sponsor:
UCB Japan Co. Ltd.
Conditions:
Epilepsy, Partial
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concom...
Eligibility Criteria
Inclusion
- Patients who completed the evaluation period (Week 16) of N165 Clinical Trial of L059
- Patients/the parent or guardian wish to continue treatment with L059 and to enter N165 Follow-up Study, and also the investigator admit the necessity of the repeated intake of the investigational drug for the patients.
Exclusion
- Patients who had not participate in N165 Clinical Trial of L059.
- Patients who had participated in N165 Clinical Trial of L059 with no intention of entering the follow-up study taking the same medication.
- Patients had not been in compliance with requirements of Protocol for N165 Clinical Trial of L059 in the course of the study.
Key Trial Info
Start Date :
September 12 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 17 2007
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT00160615
Start Date
September 12 2001
End Date
January 17 2007
Last Update
June 10 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.